FDA Is Alerting Patients And Health Care Professionals About Voluntary Withdrawal Of Oxbryta From Market Due To Safety Concerns; Says Patients And Caregivers Should Contact Their Health Care Professional About Stopping Oxbryta And Starting Another Treatment Option
Portfolio Pulse from Benzinga Newsdesk
The FDA has announced a voluntary withdrawal of Oxbryta from the market due to safety concerns. This decision impacts patients and healthcare professionals who use or prescribe this medication.
September 26, 2024 | 7:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Pfizer may be indirectly affected by the FDA's announcement regarding the withdrawal of Oxbryta due to safety concerns, as it could influence market perceptions of pharmaceutical safety.
While Pfizer is not directly involved with Oxbryta, the FDA's action could impact the pharmaceutical sector's perception regarding drug safety. However, without direct involvement, the impact on Pfizer is likely minimal.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 20